|
| 37312418 | Microfluidic Immuno-Serolomic Assay Reveals Systems Level Association with COVID-19 Pathology and Vaccine Protection. | Small Methods | 2023 |
| 37606046 | Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination. | JCI Insight | 2023 |
| 32808554 | Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. | Mult Scler | 2022 |
| 35490444 | Changes in ganglioside antibody positivity rates during the COVID-19 pandemic. | J Neuroimmunol | 2022 |
| 35713752 | Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency. | J Clin Immunol | 2022 |
| 35973344 | LRP4 antibody testing in myasthenia gravis. | J Neuroimmunol | 2022 |
| 36270950 | Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder: From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2022 |
| 36357190 | Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery: From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2022 |
| 36093346 | Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity. | bioRxiv | 2022 |
| 35095742 | Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes. | Front Neurol | 2022 |
| 33411696 | A STAT3 inhibitor ameliorates CNS autoimmunity by restoring Teff:Treg balance. | JCI Insight | 2021 |
| 34753828 | COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis. | Neurol Neuroimmunol Neuroinflamm | 2021 |
| 34364105 | B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report. | J Neuroimmunol | 2021 |
| 34284316 | Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. | Mult Scler Relat Disord | 2021 |
| 32518058 | Multiple sclerosis and COVID-19: A great opportunity for databases promoting research and collaboration. | J Neuroimmunol | 2020 |
| 30844611 | Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. | Mult Scler Relat Disord | 2019 |
| 31077854 | B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. | J Neuroimmunol | 2019 |
| 29389745 | Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center. | Clin Neuropharmacol | 2018 |
| 30157388 | Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. | N Engl J Med | 2018 |
| 30366205 | Distinct roles for Blimp-1 in autoreactive CD4 T cells during priming and effector phase of autoimmune encephalomyelitis. | J Neuroimmunol | 2018 |
| 30564621 | TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency. | Ann Clin Transl Neurol | 2018 |
| 27452124 | Therapeutic developments for autoimmune demyelinating diseases: Musings from an MD (mouse doctor). | J Neuroimmunol | 2017 |
| 28241157 | Selection of Patients With Multiple Sclerosis to Undergo Autologous Hematopoietic Stem Cell Transplantation. | JAMA Neurol | 2017 |
| 28148635 | High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. | Neurology | 2017 |
| 28878115 | IL-23R-activated STAT3/STAT4 is essential for Th1/Th17-mediated CNS autoimmunity. | JCI Insight | 2017 |
| 26954286 | Will Biomarkers Determine What Is Next in Multiple Sclerosis?: Biomarkers in Multiple Sclerosis. | JAMA Neurol | 2016 |
| 29443124 | Care of persons with MS in clinical practice: Management by majority. | Neurol Clin Pract | 2016 |
| 26621682 | Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. | Lancet Neurol | 2016 |
| 26611996 | Basal Ganglia Iron in Patients with Multiple Sclerosis Measured with 7T Quantitative Susceptibility Mapping Correlates with Inhibitory Control. | AJNR Am J Neuroradiol | 2016 |
| 27912762 | Regulation of effector function of CNS autoreactive CD4 T cells through inhibitory receptors and IL-7Rα. | J Neuroinflammation | 2016 |
| 27798157 | CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. | J Immunol | 2016 |
| 27295341 | Cortical Volume Loss and Neurologic Dysfunction in Multiple Sclerosis. | JAMA Neurol | 2016 |
| 27190026 | MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis. | Brain | 2016 |
| 27521810 | Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. | Contemp Clin Trials | 2016 |
| 27063617 | Relapses in multiple sclerosis: Relationship to disability. | Mult Scler Relat Disord | 2016 |
| 25142403 | Impact of suppressing retinoic acid-related orphan receptor gamma t (ROR)γt in ameliorating central nervous system autoimmunity. | Clin Exp Immunol | 2015 |
| 26322563 | Responsibilities of Health Care Professionals in Counseling and Educating Patients With Incurable Neurological Diseases Regarding "Stem Cell Tourism": Caveat Emptor. | JAMA Neurol | 2015 |
| 26894232 | Analysis of miRNA in Normal Appearing White Matter to Identify Altered CNS Pathways in Multiple Sclerosis. | J Autoimmune Disord | 2015 |
| 25499467 | Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosis. | Brain Behav Immun | 2015 |
| 25546364 | High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. | JAMA Neurol | 2015 |
| 25593207 | Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. | Stem Cells Transl Med | 2015 |
| 25531742 | Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? | JAMA Neurol | 2015 |
| 24587891 | First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks. | Ther Adv Chronic Dis | 2014 |
| 25045248 | Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. | Drug Des Devel Ther | 2014 |
| 25084179 | Is T-bet a potential therapeutic target in multiple sclerosis? | J Interferon Cytokine Res | 2014 |
| 23338729 | Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. | JAMA Neurol | 2013 |
| 24175156 | Multiple sclerosis: Five new things. | Neurol Clin Pract | 2013 |
| 23530268 | Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. | JAMA Neurol | 2013 |
| 22078708 | miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. | J Neuroimmunol | 2012 |
| 23650470 | New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. | J Cent Nerv Syst Dis | 2012 |